Oddo BHF Asset Management Sas Sells 240,766 Shares of Boston Scientific Corporation $BSX

Oddo BHF Asset Management Sas decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 42.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 327,138 shares of the medical equipment provider’s stock after selling 240,766 shares during the period. Oddo BHF Asset Management Sas’ holdings in Boston Scientific were worth $20,528,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Outfitters Financial LLC raised its holdings in Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after acquiring an additional 110 shares during the period. Natural Investments LLC boosted its holdings in shares of Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after acquiring an additional 112 shares during the period. Patton Fund Management Inc. grew its position in shares of Boston Scientific by 5.5% in the fourth quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 118 shares in the last quarter. Bridgewater Advisors Inc. grew its position in shares of Boston Scientific by 1.2% in the fourth quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock valued at $921,000 after purchasing an additional 123 shares in the last quarter. Finally, Earned Wealth Advisors LLC raised its stake in shares of Boston Scientific by 5.2% during the 4th quarter. Earned Wealth Advisors LLC now owns 2,647 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 131 shares during the period. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue of $5.442 billion exceeded expectations of roughly $5.36 billion. Sales increased 7.5% year over year, led by 8.3% growth in Cardiovascular and strong international performance. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase program and announced a $1.5 billion investment in MiRus, including an option to acquire its transcatheter aortic valve replacement business. These actions could support long-term growth and per-share results. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Boston Scientific is beginning a global restructuring program expected to cost $700 million to $800 million through 2029, with anticipated headcount reductions and potential annual cost savings of about $500 million. Near-term charges may weigh on results, while savings could improve margins later. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: The company reduced full-year 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the approximately $3.36 consensus. Third-quarter EPS and revenue guidance also trail analyst expectations.
• Negative Sentiment: Management cited softer-than-expected Watchman demand, unexpected challenges in the heart-implant market and competition affecting the electrophysiology business. The lower outlook overshadowed the quarterly beat and raised concerns about growth execution. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting price targets, including BTIG to $60 from $65, although it maintained a Buy rating. BTIG lowers Boston Scientific price target

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $46.06 on Thursday. The stock has a market cap of $68.47 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 0.88 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business has a 50-day simple moving average of $46.57 and a 200 day simple moving average of $62.73. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Royal Bank Of Canada dropped their price objective on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research report on Wednesday. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Mizuho cut their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Evercore set a $65.00 price objective on shares of Boston Scientific in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.